Context Therapeutics Inc.

$2.23+2.76%(+$0.06)
TickerSpark Score
58/100
Mixed
73
Valuation
20
Profitability
55
Growth
84
Health
60
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNTX research report →

52-Week Range56% of range
Low $0.49
Current $2.23
High $3.62

Companywww.contexttherapeutics.com

Context Therapeutics Inc. , a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers.

CEO
Martin A. Lehr
IPO
2021
Employees
12
HQ
Philadelphia, PA, US

Price Chart

+228.52% · this period
$3.36$1.96$0.55May 20Nov 18May 20

Valuation

Market Cap
$204.89M
P/E
-5.28
P/S
0.00
P/B
4.07
EV/EBITDA
-3.54
Div Yield
0.00%

Profitability

Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-59.95%
ROIC
-82.91%

Growth & Income

Revenue
$0 · 0.00%
Net Income
$-36,123,615 · -35.17%
EPS
$-0.38 · 17.39%
Op Income
$-39,702,631
FCF YoY
9.87%

Performance & Tape

52W High
$3.62
52W Low
$0.49
50D MA
$2.57
200D MA
$1.67
Beta
1.57
Avg Volume
843.08K

Get TickerSpark's AI analysis on CNTX

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Recent Insider Transactions

DateInsiderTypeShares
Feb 19, 26Levit Alex C.other270,000
Feb 19, 26Minai-Azary Jennifer Lynnother275,000
Feb 19, 26Chagin Karen Deborahother290,000
Feb 19, 26Lehr Martin A.other815,000
Jun 12, 25Pasternak Andyother138,900
Jun 12, 25Kantoff Philip W.other123,500
Jun 12, 25Smith Karen L.other123,500
Jun 12, 25Stacey Jennifer Evansother123,500
Jun 12, 25Walker Luke Nathanielother123,500
Jun 12, 25West Lindaother123,500

Our CNTX Coverage

We haven't published any research on CNTX yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate CNTX Report →

Similar Companies